AbbVie (NYSE: ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and capabilities of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world’s most complex and serious diseases. In 2013, AbbVie will employ approximately 21,000 people worldwide and markets medicines in more than 170 countries.
Accomplished cellular immunologist who will set strategy in drug discovery and development, in arthritis and other autoimmune indications. The successful candidate will apply their expertise to a portfolio of small molecule and biologic drug discovery programs to prioritize targets, guide drug discovery strategy, identify specific disease indication opportunities, develop target engagement readouts for lead compound evaluation and biomarker use, and lead or advise advanced discovery programs.
PhD or equivalent in Immunology, Cell Biology, Pharmacology, or a related discipline, with 10-20 years postdoctoral research experience in the pharmacologic modulation of immune-based disease mechanisms. Expertise in the field of T Cell biology is required. Skill in leading, collaborating with and mentoring colleagues is expected.
The successful candidate will have an extensive record of accomplishment in cellular immunology research as evidenced by a high-quality publication record and/or a series of successful preclinical drug discovery programs. Preference will be given to applicants with cellular immunology leadership experience in an academic or industrial environment. Experience in leading large cross-site or collaborative project teams is desired.
Position can be filled at a lower level based on the experience of the applicant.
PhD or equivalent in Immunology, Cell Biology, Pharmacology, or a related discipline.
Significant Work Activities and Conditions
Continuous sitting for prolonged periods ( more than 2 consecutive hours in an 8 hour day)
RESEARCH AND DEVELOPMENT
Yes, 20 % of the Time